NEW YORK — Atlanta Braves outfielder Jurickson Profar faces a 162-game suspension by Major League Baseball for a possible second failed test for a performance-enhancing drug, a person familiar with the issue told The Associated Press on Tuesday.
The person spoke on condition of anonymity because the process, first reported by ESPN, was ongoing.
Profar intends to ask the players association to file a grievance to appeal any discipline to baseball’s independent arbitrator, Martin F, Scheinman, a second person familiar with the process said, also on condition of anonymity because no announcement had been made.
Because this would be Profar’s second infraction, an appeal would take place after a suspension was announced.
An All-Star in 2024 with the San Diego Padres, Profar was suspended for 80 games last March 31 after a positive test for Chorionic Gonadotrophin (hCG), a hormone that helps production of testosterone. He issued a statement then saying: “I would never willingly take a banned substance, but I take full responsibility and accept MLB’s decision.”
His agent, Dan Lozano, did not immediately respond to a request for comment.
Profar homered in his return from suspension July 2 and finished with a .245 average, 14 homers, 43 RBIs and a .787 OPS in 80 games. He batted .280 in 2024, when he set career highs with 24 homers, 85 RBIs and an .839 OPS.
Profar said at the start of spring training that he had sports hernia surgery in November, requiring a six-week recovery. He has appeared in four spring training games this year, going 3-for-10 with three RBIs.
A native of Curaçao, Profar had been set to play for the Netherlands in the World Baseball Classic.
Under the suspension, he would be ineligible for the postseason.
Profar would lose his $15 million salary for this year as part of the three-year, $42 million contract through 2027 that he signed with the Braves in January 2025. He lost half of his $12 million salary last year because of the initial suspension.
He would be the seventh player suspended 162 games for a second PED infraction after New York Mets pitcher Jenrry Mejia (July 2015), Cleveland outfielder Marlon Byrd (June 2016), free-agent catcher Cody Stanley (July 2016), Houston Astros pitcher Francis Martes (February 2020), Mets second baseman Robinson Canó (November 2020) and Milwaukee Brewers pitcher J.C. Mejia (September 2023).
Mejia received a lifetime ban in February 2016 after a third positive test, the only player to be given a permanent ban since drug testing with penalties started in 2004.
Four players have been suspended previously this year for positive tests, including free-agent outfielder Max Kepler for 80 games under the major-league program after a positive test for Epitrenbolone.
After the offseason signing of left fielder Mike Yastrzemski to a two-year, $23 million deal, Profar had been targeted to be the Braves’ primary designated hitter.
When catcher Sean Murphy returns from a hip injury, perhaps in May, 2025 NL Rookie of the Year Drake Baldwin could fill in at DH when not behind the plate.
With Yastrzemski, Michael Harris and Ronald Acuña Jr. in the outfield, Eli White could be a DH option. The Braves also are without projected starting shortstop Ha-seong Kim because of a finger injury. Mauricio Dubon, expected to serve a utility role, is scheduled to open the season as the starting shortstop.
The loss of Profar could create an opportunity for Dominic Smith, who signed a minor-league deal Feb. 17.
AP’s Charles Odum contributed.